+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Development Market by Source, Type, Disease Indication, Phase, Service Type, End-User - Global Forecast 2025-2030- Product Image
Biologics Contract Development Market by Source, Type, Disease Indication, Phase, Service Type, End-User - Global Forecast 2025-2030- Product Image
Sale

Biologics Contract Development Market by Source, Type, Disease Indication, Phase, Service Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011399
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Contract Development Market grew from USD 6.54 billion in 2023 to USD 7.30 billion in 2024. It is expected to continue growing at a CAGR of 11.79%, reaching USD 14.28 billion by 2030.

The biologics contract development market encompasses the outsourcing of biologics development services, offering expertise in activities like cell line development, process and analytical development, and clinical trial management. This market's necessity is propelled by the rising demand for biologics, complex molecules that require specialized development capabilities beyond the reach of many in-house teams. Key applications include monoclonal antibodies, vaccines, and gene therapy products, catering to end-use sectors like pharmaceuticals, biotechnology, and clinical research organizations. Growth is driven by increasing R&D investments, the expanding pipeline of biologic products, and the shift towards personalized medicine. Emerging opportunities are evident in technological advancements in bioprocessing, the utilization of AI and machine learning for optimized process development, and the growing adoption of single-use technologies which enhance flexibility and reduce contamination risks. However, the market faces challenges such as stringent regulatory complexities, high capital requirements, and the need for highly skilled labor, creating a barrier for smaller entities. There is also increased competition from larger, established providers who dominate market share. Innovation areas ripe for exploration include advanced biomanufacturing techniques, the development of biosimilars, and innovations in cell and gene therapy processes. For business growth, tapping into underserved regions with emerging biotech sectors presents a considerable opportunity, as does leveraging partnerships to expand service offerings and market reach. Companies could benefit from investing in modular manufacturing facilities to address production scale and efficiency demands, while ensuring compliance with multifaceted global regulations. Overall, the biologics contract development market is characterized by rapid innovation, high collaboration, and significant investment in novel technologies. This dynamic environment provides a fertile ground for businesses to innovate and adapt, ensuring they stay at the forefront of a highly competitive yet rewarding industry.

Understanding Market Dynamics in the Biologics Contract Development Market

The Biologics Contract Development Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing demand for vaccine and biosimilar production
    • Government initiatives encouraging biologics activities
    • Improved operational efficiency and cost saving with biologics CDO
  • Market Restraints
    • Communication issues between end-user and CDO
  • Market Opportunities
    • Technological advancements in biologics development systems
    • Investments in new biologics contract development services expansion
  • Market Challenges
    • Concerns associated with breach of intellectual property

Exploring Porter’s Five Forces for the Biologics Contract Development Market

Porter’s Five Forces framework further strengthens the insights of the Biologics Contract Development Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biologics Contract Development Market

External macro-environmental factors deeply influence the performance of the Biologics Contract Development Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biologics Contract Development Market

The Biologics Contract Development Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biologics Contract Development Market

The Biologics Contract Development Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biologics Contract Development Market

The Biologics Contract Development Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JRS PHARMA GmbH & Co. KG, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Source
    • Mammalian
    • Microbial
  • Type
    • Molecular Therapy
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Vaccines
  • Disease Indication
    • Cardiovascular Disorders
    • Hematological Disorders
    • Immunological Disorders
    • Oncology
  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Preclinical
  • Service Type
    • Cell Line Development
      • Mammalian
      • Microbial
    • Process Development
      • Downstream
        • Impurity, Isolation, & Identification
        • Pharmaceutical Analysis
        • Physicochemical Characterization
      • Upstream
        • Mammalian
        • Microbial
  • End-User
    • Biopharmaceutical Companies
    • Research Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for vaccine and biosimilar production
5.1.1.2. Government initiatives encouraging biologics activities
5.1.1.3. Improved operational efficiency and cost saving with biologics CDO
5.1.2. Restraints
5.1.2.1. Communication issues between end-user and CDO
5.1.3. Opportunities
5.1.3.1. Technological advancements in biologics development systems
5.1.3.2. Investments in new biologics contract development services expansion
5.1.4. Challenges
5.1.4.1. Concerns associated with breach of intellectual property
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biologics Contract Development Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Microbial
7. Biologics Contract Development Market, by Type
7.1. Introduction
7.2. Molecular Therapy
7.3. Monoclonal Antibodies
7.4. Recombinant Proteins
7.5. Vaccines
8. Biologics Contract Development Market, by Disease Indication
8.1. Introduction
8.2. Cardiovascular Disorders
8.3. Hematological Disorders
8.4. Immunological Disorders
8.5. Oncology
9. Biologics Contract Development Market, by Phase
9.1. Introduction
9.2. Phase I
9.3. Phase II
9.4. Phase III
9.5. Preclinical
10. Biologics Contract Development Market, by Service Type
10.1. Introduction
10.2. Cell Line Development
10.2.1. Mammalian
10.2.2. Microbial
10.3. Process Development
10.3.1. Downstream
10.3.1.1. Impurity, Isolation, & Identification
10.3.1.2. Pharmaceutical Analysis
10.3.1.3. Physicochemical Characterization
10.3.2. Upstream
10.3.2.1. Mammalian
10.3.2.2. Microbial
11. Biologics Contract Development Market, by End-User
11.1. Introduction
11.2. Biopharmaceutical Companies
11.3. Research Laboratories
12. Americas Biologics Contract Development Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biologics Contract Development Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biologics Contract Development Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET RESEARCH PROCESS
FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT MARKET DYNAMICS
TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 83. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 84. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 135. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 136. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 145. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 146. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 165. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 166. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 225. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 226. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 249. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 250. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 254. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 255. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 256. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 257. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 259. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 260. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 261. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 262. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 263. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 264. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 265. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 266. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 267. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 269. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 270. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 271. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 272. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 273. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 274. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 275. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 276. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 277. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 278. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 279. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 281. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 282. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 283. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 284. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 285. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 286. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 287. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 289. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 290. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 291. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 292. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 293. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 294. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 295. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 296. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 297. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 309. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 310. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 311. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 312. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 313. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (US

Companies Mentioned

The leading players in the Biologics Contract Development market, which are profiled in this report, include:
  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JRS PHARMA GmbH & Co. KG
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.28 Billion
Compound Annual Growth Rate11.7%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Biologics Contract Development & Manufacturing Organization Market by Type, Product Type, Disease Indication, Service Type, End-User - Global Forecast 2025-2030 - Product Image

Biologics Contract Development & Manufacturing Organization Market by Type, Product Type, Disease Indication, Service Type, End-User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Biologics Contract Manufacturing Market by Product, Platform, Therapeutic Area, Scale of Operation - Global Forecast 2025-2030 - Product Image

Biologics Contract Manufacturing Market by Product, Platform, Therapeutic Area, Scale of Operation - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Biologics Contract Development Global Market Report 2024 - Product Image

Biologics Contract Development Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From

About the Bio CMO Market

The Bio CMO market is a subset of the biopharmaceutical industry, which focuses on the production of biopharmaceuticals. Bio CMOs provide contract manufacturing services to biopharmaceutical companies, such as drug development, clinical trial materials, and commercial production. These services are typically tailored to the specific needs of the customer, and can include process development, analytical services, and quality control. Bio CMOs are also responsible for the production of biopharmaceuticals, including the manufacture of active pharmaceutical ingredients (APIs) and the formulation of finished dosage forms. Bio CMOs are an important part of the biopharmaceutical industry, as they provide the necessary services to enable the development and production of biopharmaceuticals. Examples of companies in the Bio CMO market include Lonza, Boehringer Ingelheim, Catalent, and Patheon. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.